Patient, disease, and transplant characteristics
| . | UD-HSCT . |
|---|---|
| No. of patients | 1011 |
| Follow-up in months, median (IQR) | 26 (24-29) |
| Year of HSCT, n (%) | |
| 2011-2013 | 10 (1) |
| 2014-2015 | 63 (6) |
| 2016-2017 | 187 (18) |
| 2018-2019 | 330 (33) |
| 2020-2021 | 421 (42) |
| Age, median (range), y | 54 (18-77) |
| Sex, n (%) | |
| Male | 566 (56) |
| Female | 446 (44) |
| CMV serologic status, n (%) | |
| Positive | 747 (75) |
| Negative | 254 (25) |
| Missing | 10 |
| Karnofsky score at transplant, n (%) | |
| <90 | 243 (25) |
| ≥90 | 744 (75) |
| Missing | 24 |
| HCT-CI, n (%) | |
| 0 | 510 (50) |
| 1-2 | 237 (23) |
| ≥ 3 | 264 (26) |
| Cytogenetic risk, n (%) | |
| Standard | 83 (9) |
| Intermediate | 612 (67) |
| Adverse | 213 (24) |
| Missing | 103 |
| FLT3-ITD, n (%) | |
| Absent | 346 (64) |
| Present | 199 (36) |
| Missing | 466 |
| NPM1, n (%) | |
| Absent | 317 (62) |
| Present | 192 (38) |
| Missing | 502 |
| Disease status at transplant, n (%) | |
| CR1 | 837 (83) |
| CR2 | 174 (17) |
| Conditioning intensity, n (%) | |
| Myeloablative | 548 (54) |
| Reduced intensity | 463 (46) |
| In vivo T-cell depletion, n (%) | |
| No | 837 (83) |
| Yes | 174 (17) |
| GVHD prophylaxis, n (%) | |
| PTCy + calcineurin inhibitor + MMF | 560 (56) |
| PTCy + calcineurin inhibitor | 258 (25) |
| PTCy + Sirolimus + MMF | 94 (9) |
| PTCy + other | 99 (10) |
| . | UD-HSCT . |
|---|---|
| No. of patients | 1011 |
| Follow-up in months, median (IQR) | 26 (24-29) |
| Year of HSCT, n (%) | |
| 2011-2013 | 10 (1) |
| 2014-2015 | 63 (6) |
| 2016-2017 | 187 (18) |
| 2018-2019 | 330 (33) |
| 2020-2021 | 421 (42) |
| Age, median (range), y | 54 (18-77) |
| Sex, n (%) | |
| Male | 566 (56) |
| Female | 446 (44) |
| CMV serologic status, n (%) | |
| Positive | 747 (75) |
| Negative | 254 (25) |
| Missing | 10 |
| Karnofsky score at transplant, n (%) | |
| <90 | 243 (25) |
| ≥90 | 744 (75) |
| Missing | 24 |
| HCT-CI, n (%) | |
| 0 | 510 (50) |
| 1-2 | 237 (23) |
| ≥ 3 | 264 (26) |
| Cytogenetic risk, n (%) | |
| Standard | 83 (9) |
| Intermediate | 612 (67) |
| Adverse | 213 (24) |
| Missing | 103 |
| FLT3-ITD, n (%) | |
| Absent | 346 (64) |
| Present | 199 (36) |
| Missing | 466 |
| NPM1, n (%) | |
| Absent | 317 (62) |
| Present | 192 (38) |
| Missing | 502 |
| Disease status at transplant, n (%) | |
| CR1 | 837 (83) |
| CR2 | 174 (17) |
| Conditioning intensity, n (%) | |
| Myeloablative | 548 (54) |
| Reduced intensity | 463 (46) |
| In vivo T-cell depletion, n (%) | |
| No | 837 (83) |
| Yes | 174 (17) |
| GVHD prophylaxis, n (%) | |
| PTCy + calcineurin inhibitor + MMF | 560 (56) |
| PTCy + calcineurin inhibitor | 258 (25) |
| PTCy + Sirolimus + MMF | 94 (9) |
| PTCy + other | 99 (10) |
HCT-CI, hematopoietic cell transplantation specific comorbidity index.